News articles about Mazor Robotics (NASDAQ:MZOR) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mazor Robotics earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical instruments supplier an impact score of 47.1117354216876 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Sturgeon Ventures LLP Buys NVIDIA Corp, Netflix Inc, Mazor Robotics, Sells Ashland Global Holdings Inc, United … (gurufocus.com)
- Global Hospital and Pharmacy Robots Market Review 2018-2025 Mazor Robotics, Stryker, ARxIUM (newszak.com)
- Spinal Surgical Robots Market Share (2018-2025): Intuitive Surgical, Inc., SpineFrontier, Inc., Kuka AG, Medtech SA … (mymarketgazette.com)
- Research Analysts Issue Forecasts for Mazor Robotics Ltd -‘s Q3 2018 Earnings (MZOR) (americanbankingnews.com)
Several analysts have commented on MZOR shares. ValuEngine raised shares of Mazor Robotics from a “hold” rating to a “buy” rating in a research report on Friday. BidaskClub lowered shares of Mazor Robotics from a “hold” rating to a “sell” rating in a research report on Wednesday, June 20th. Zacks Investment Research raised shares of Mazor Robotics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 29th. Wells Fargo & Co lifted their price objective on shares of Mazor Robotics from $56.00 to $62.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 15th. Finally, Cantor Fitzgerald started coverage on shares of Mazor Robotics in a research report on Thursday, May 31st. They issued a “neutral” rating and a $57.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. Mazor Robotics has an average rating of “Hold” and a consensus price target of $61.08.
MZOR stock traded up $0.01 during mid-day trading on Friday, hitting $47.70. The company had a trading volume of 2,670 shares, compared to its average volume of 430,914. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -95.40 and a beta of 1.51. Mazor Robotics has a 12 month low of $41.60 and a 12 month high of $76.56.
Mazor Robotics (NASDAQ:MZOR) last announced its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.13). Mazor Robotics had a negative return on equity of 7.17% and a negative net margin of 12.80%. The company had revenue of $13.20 million during the quarter, compared to the consensus estimate of $17.02 million. During the same period in the prior year, the firm posted ($0.05) EPS. The business’s revenue was down 14.8% on a year-over-year basis. analysts expect that Mazor Robotics will post -0.12 earnings per share for the current year.
Mazor Robotics Company Profile
Mazor Robotics Ltd., together with its subsidiaries, engages in the development, production, and marketing of medical devices for supporting surgical procedures in the fields of orthopedics and neurosurgery in the United States and internationally. It operates in the field of computer assisted surgery that enable the use of surgical instruments with high precision and minimal invasiveness and that simplifies complex surgical procedures.
Further Reading: Marijuana Stocks
Receive News & Ratings for Mazor Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics and related companies with MarketBeat.com's FREE daily email newsletter.